MET Mutation Detection Kit

MET Mutation Detection Kit
Qualitative detection of exon 14 skipping mutation in MET gene
MET alterations that result in exon 14 skipping are found in approximately 3~4% of lung adenocarcinoma patients. Exon 14 skipping results in the deletion of the juxtamembrane domain of MET, which leads to enhanced signaling through the MET receptor pathway.  Studies have shown that NSCLC patients harboring MET with exon 14 skipping have increased sensitivity to MET-targeted therapies, such as crizotinib, cabozantinib, etc.
AmoyDx® MET Mutation Detection Kit is a real-time PCR assay for qualitative detection of exon 14 skipping mutation in MET gene in human total RNA extracted from NSCLC formalin-fixed paraffin-embedded (FFPE) tissue samples.

Technological Principles
The kit comprises specific primers and fluorescent probes to detect gene mutation in real-time PCR assay, which combines reverse transcription and PCR amplification in one step. The target region of FFPE RNA is transcribed into cDNA with the action of reverse transcriptase and specific primers. The MET variant cDNA is amplified by specific primers and the mutant amplicon is detected by fluorescent probe labeled with FAM, while reference gene amplicon is detected by fluorescent probe labeled with VIC.